John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Hansson E, Hagberg K, Cawson M, Brodtkorb TH. Patients with unilateral transfemoral amputation treated with a percutaneous osseointegrated prosthesis. Bone Joint J. 2018 Apr 1;100-B(4):527-34.
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Cueto HT, Riis AH, Hatch EE, Wise LA, Rothman KJ, Sørensen HT, Mikkelsen EM. Folic acid supplementation and fecundability: a Danish prospective cohort study. Eur J Clin Nutr. 2016 Jan;70(1):66-71. doi: 10.1038/ejcn.2015.94
Granero R, Fernandez-Aranda F, Aymami N, Gomez-Pena M, Fagundo AB, Sauchelli S, Del Pino-Gutierrez A, Moragas L, Savvidou LG, Islam MA, Tarrega S, Menchon JM, Jimenez-Murcia S. Subtypes of pathological gambling with concurrent illegal behaviors. J Gambl Stud. 2015 Dec;31(4):1161-78. doi: 10.1007/s10899-014-9499-5.
Sharp L, Donnelly D, Hegarty A, Carsin AE, Deady S, McCluskey N, Gavin A, Comber H. Risk of several cancers is higher in urban areas after adjusting for socioeconomic status. Results from a two-country population-based study of 18 common cancers. J Urban Health. 2014 Jun;91(3):510-25. doi: 10.1007/s11524-013-9846-3
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.